Evidence map›Paper›PMID 41515921›Full record

ArticleInternational journal of molecular sciences2025

NLRP3 Inflammasome as Potential Predictor of Non-Responsiveness to Immunosuppressive Treatment in Lupus Nephritis.

Camila Barbosa Lyra de Oliveira, Werbson Lima Guaraná, Gisele Vajgel, Braziliano Miguel da Silva Júnior, Camilla Albertina Dantas Lima, Stanley de Almeida Araújo, Fabrício Oliveira Souto, Denise Maria do Nascimento Costa, Lucila Maria Valente, Paula Sandrin-Garcia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Camila Barbosa Lyra de OliveiraDivision of Nephrology, Clinical Hospital, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
Werbson Lima GuaranáInstitute Keizo Asami (iLIKA), Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.ORCID 0000-0003-1806-5219
Gisele VajgelDivision of Nephrology, Clinical Hospital, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.ORCID 0000-0002-2606-3638
Braziliano Miguel da Silva JúniorPrograma de Pós-Graduação em Biologia Aplicada à Saúde (PPGBAS), Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.ORCID 0000-0001-5615-4322
Camilla Albertina Dantas LimaInstitute Keizo Asami (iLIKA), Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.ORCID 0000-0003-0320-3674
Stanley de Almeida AraújoNephropathology Institute, Belo Horizonte 30150-281, Minas Gerais, Brazil.ORCID 0000-0001-9996-4405
Fabrício Oliveira SoutoAgreste Science Center, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.ORCID 0000-0002-2392-8499
Denise Maria do Nascimento CostaDivision of Nephrology, Clinical Hospital, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
Lucila Maria ValenteDivision of Nephrology, Clinical Hospital, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
Paula Sandrin-GarciaPrograma de Pós-Graduação em Biologia Aplicada à Saúde (PPGBAS), Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.ORCID 0000-0003-4641-7429

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

Lupus nephritis (LN) can affect up to 60% of patients with systemic lupus erythematosus (SLE). The NLRP3 inflammasome has been implicated in the pathogenesis of LN. This study aimed to evaluate the role of the NLRP3 inflammasome as a predictor of response to immunosuppressive treatment in patients with active LN. A prospective cohort study was conducted with 20 adult patients with active LN, classes III, IV, and V, from January 2021 to September 2023. Patients were followed up at biopsy (T0) and 6 months (T6) and 12 months (T12) after treatment and classified according to the primary efficacy renal response (PERR) at 12 months. Gene expression of

Indexed as

Immunosuppressive AgentsInflammasomesLupus NephritisNLR Family, Pyrin Domain-Containing 3 ProteinAdultBiomarkersCaspase 1FemaleHumansInterleukin-1betaMaleProspective StudiesBiomarkersCaspase 1Immunosuppressive AgentsInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanbiomarkerdisease activitylupus nephritisNLRP3 inflammasomeprognosissystemic lupus erythematosus

Identifiers

PMID41515921
PMCPMC12785384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.